[Schizophrenia in half-sisters].

Fortschr Neurol Psychiatr

Published: June 1986

Little is known about identical schizophrenic disorders in half-siblings. In this study, we report on one family with six half-siblings (from 3 different marriages of the mother) three of whom developed schizophrenic disorders. Based on psychodynamic and psychosocial viewpoints, we studied the family environment and premorbid characteristics. We also investigated the conditions and psychoreactive factors leading up to the onset or relapse of the illness. We compared the mental developments, particularly the personal relationships of the schizophrenic half-siblings with those of the normal half-siblings. We also attempted to clarify the pathological conditions on the hand and the protective factors on the other hand.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2007-1001866DOI Listing

Publication Analysis

Top Keywords

schizophrenic disorders
8
[schizophrenia half-sisters]
4
half-sisters] identical
4
identical schizophrenic
4
half-siblings
4
disorders half-siblings
4
half-siblings study
4
study report
4
report family
4
family half-siblings
4

Similar Publications

Background: Glial cell line-derived neurotrophic factor (GDNF) has emerged as a potential biomarker for schizophrenia (SCZ). However, GDNF levels remain unclear in affected individuals compared to healthy controls. Therefore, we aimed to calculate a pooled estimate of GDNF levels in patients with SCZ in comparison with healthy controls.

View Article and Find Full Text PDF

Dysbiosis is associated with the behavioral phenotype observed in the triple-hit Wisket rat model of schizophrenia.

Prog Neuropsychopharmacol Biol Psychiatry

January 2025

Department of Physiology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary. Electronic address:

Comorbidities between gastrointestinal diseases and psychiatric disorders have been widely reported, with the gut-brain axis implicated as a potential biological basis. Thus, dysbiosis may play an important role in the etiology of schizophrenia, which is barely detected. Triple-hit Wisket model rats exhibit various schizophrenia-like behavioral phenotypes.

View Article and Find Full Text PDF

The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia experiencing acute psychosis. This random-effects model pairwise meta-analysis of those three trials found that xanomeline-trospium was comparable to placebo in terms of all-cause discontinuation, discontinuation rate due to adverse events, Simpson-Angus Scale score change, Barnes Akathisia Rating Scale score change, body weight change, body mass index change, blood pressure change, serum total cholesterol change, blood glucose change, QTc interval changes, and the incidence of headache, somnolence, insomnia, dizziness, akathisia, agitation, tachycardia, gastroesophageal reflux disease, diarrhea, increased weight, and decreased appetite. However, xanomeline-trospium was associated with a higher incidence of at least one adverse event, dry mouth, hypertension, nausea, vomiting, dyspepsia, and constipation, and increased serum triglyceride compared with placebo.

View Article and Find Full Text PDF

Distribution and correlates of long-acting injectable antipsychotic use among community mental health center patients.

Psychiatry Res

January 2025

South Carolina Department of Mental Health, 220 Executive Dr, Greer, SC 29651, United States; Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, 15 Medical Park, Suite 301, Columbia, SC 29203, United States.

Although long-acting injectable antipsychotics (LAIs) are an important pharmaceutical option in the management of schizophrenia and related disorders, little is known about patient characteristics related to LAI use in real-world outpatient settings. We analyzed electronic medical records from 41,401 patients who received psychiatric services from one of 16 regional mental health centers operated by the South Carolina Department of Mental Health in 2022. We compared the use of first- and second-generation LAIs and oral antipsychotics by sociodemographic (age, gender, race/ethnicity, zip code, payment source) and clinical characteristics (psychiatric diagnoses, service use).

View Article and Find Full Text PDF

Delusional misidentification syndromes (DMS) are rare neuropsychiatric syndromes. Most of the available data on DMS is from the developed countries. The present retrospective analysis was conducted on patients utilizing the psychiatry services in a North Indian tertiary care hospital.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!